Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
G.FrankL
Key benefits Why people compare it 1 14.9% mean body weight reduction demonstrated in STEP 1 trial (N=1,961) 2 20% reduction in major adverse cardiovascular events in SELECT trial (N=17,604) 3 Significant reduction in appetite and food cravings via hypothalamic POMC/CART activation 4 Improved glycemic control with glucose-dependent insulin secretion potentiation 5 Once-weekly dosing enabled by 165-hour plasma half-life and albumin binding 6 86.4% of STEP 1 participants achieved at least 5% body weight loss 7 Demonstrated NAFLD/NASH improvement with reduction in liver fat content 8 Well-characterized safety profile from over 30,000 participants across STEP and SELECT programs Deep research Semaglutide (chemical name: N-epsilon26-[2-(2-[2-(2-[2-(2-((S)-2-carboxy-3-((1S,2R)-3-carboxy-1-(carboxymethyl-carbamoyl)-propylcarbamoyl)-propionylamino)-ethoxy)-ethoxy)-acetylamino]-ethoxy)-ethoxy)-acetyl]-[Aib8,Arg34]-GLP-1-(7-37)-peptide) is a 39-amino-acid peptide with a molecular weight of 4,113.58 Da
Eating smaller meals and avoiding high-fat foods during the adjustment period can also help
In clinical studies, once-weekly administration of the GLP-1 agonist semaglutide in knee OA patients with obesity reduced patient-reported pain scores (WOMAC) over 68 weeks compared with placebo
Based on our own analysis of publicly available data on U.S
Ive had an excellent experience getting on a weight loss drug with Sanctuary
